Effect of Recombinant Human Erythropoietin on Apoptosis of Neural Cells in Fetal Rats after Intrauterine Hypoxic-ischemic Injury

MA Yu-shan, ZHOU Jun, LIU Hui, DU Yu, LIN Xue-mei

Abstract

To investigate the effect of recombine human erythropoietin (rhEPO) on apoptosis of neural cells in fetal rats after intrauterine hypoxic-ischemic injury. Methods Twenty SD rats on 19 days of pregnancy were divided into rhEPO (2500 U/kg, 5000 U/kg, 7500 U/kg) treated groups, ischemia-reperfusion (I/R) group and sham-operated group (4 rats in each group). Intrauterine hypoxic-ischemic injury of fetal rat was induced by bilateral occlusion of utero-ovarian artery for 20 min. rhEPO was injected into the rats in rhEPO treated group through the caudal vein 30 min before hypoxic-ischemic injury while saline was used in the other two groups. There was no hypoxic-ischemic injury in sham-operated group. The death rate of fetal rats was evaluated at 24 h after the operation, and then the brain samples of fetal rats were harvested. The expression of Caspase-3 protein was observed by immunohistochemistry. Neuroapoptosis was measured by TdT mediated dUTP-biotin nick end labeling (TUNEL) staining. Results Death rates of fetal rats in rhEPO treated groups decreased compared with the I/R group (P<0.05). Compared with the I/R group, there was less expression of copious Caspase-3 in rhEPO treated group (P<0.01). The expression of Caspase-3 was decreased in the rhEPO treated groups with the increase of rhEPO dose (P<0.01). Compared with the I/R group, the death rate of fetal rats in rhEPO treated groups decreased (P<0.05), the number of apoptosis cells also decreased obviously (P<0.01). The anti-apoptosis effect of 5000 U/kg rhEPO was similar to 7500 U/kg rhEPO, but better than 2500 U/kg rhEPO (P<0.01). Conclusion rhEPO can inhibit the apoptosis of fetal rat brain cells after intrauterine hypoxic-ischemic injury.

 

Keywords: Recombinant human erythropoietin, Hypoxic-ischemic, Apoptosis, Neuroprotective

 

Full Text:

PDF


References


Verklan MT. The chilling details; hypoxic-ischemic encephalopathy. J Perinat Neonat Nurs,2009; 23(1): 59-68.

McPherson RJ. Juul SE. Recent trends in erythropoietin- mediated neuroprotection. Int J Dev Neurosci, 2008; 26 ( 1 ): 103-111.

Tanaka M. Natori M, Ishimoto H. et at, PZxperimental growth retardation produced by transient period of uteroplacental ischemia in pregnant Sprague-Dawley rats. Am J Obstet Gynecol, 1994; 171 (5): 1231-1234.

Blomgren K, Leist M, Groc L. Pathological apoptosis in the developing brain. Apoptosis,2007; 12(5) ;993-1010.

Gene S, Koroglu TF, Gene K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci, 2004; 22 ( 2 ); 105- 119.

Yu X. Shacka JJ. Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development,2002; 129(2):505-516.

McPherson RJ. Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology, 2007 ; 91 (1): 36-43.

Kaur C, Ling EA. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res,2008;5( 1) -71-81.

Statler РА, McPherson RJ, Bauer LA, et al. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res, 2007 ; 61 ( 6 ): 671-675.

Gassnann M. Heinicke К. Soliz J, et al. Non-erythroid functions of erythropoietin. Adv Exp Med Biol.2003;543;323- 330.

Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol,2008;414 :13-21.


Refbacks

  • There are currently no refbacks.